Please login to the form below

Not currently logged in
Email:
Password:

France, Germany and Spain join list of countries banning Novartis vaccines

Flu vaccines Agrippal and Fluad withdrawn after some batches found to be contaminated

France, Germany and Spain have joined Switzerland, Austria and Italy in banning flu vaccines produced by Novartis after small particles were found in batches of both Agrippal and Fluad.

In France, Health Minister Marisol Touraine called for all doses of Agrippal to be withdrawn from the market, although she emphasised that there was no known risk for patients using the vaccine in France.

The nation's stance, which doesn't extend to Fluad, is pending action from the European Medicines Agency (EMA) regarding the matter, despite vaccines being the responsibility of member states.

The Agency can, however, be requested to support country-specific issues by individual governments.

France's decision mirrors that of Germany, which also said it would ban four batches of Agrippal – marketed in the country as Begripal. In addition, one batch of the Fluad vaccine will also be withdrawn.

Like France, Germany's Paul Ehrlich Institute, which is the vaccines division of the Ministry of Health, said that no adverse events had been reported in patients using the vaccine, but measures were still necessary.

Professor Klaus Cichutek, president of the Institute, said: “In the interests of risk management and the safety of consumers, it is necessary to withdraw approval for certain batches of vaccines, as particles have been found in the vaccines and the potential for serious side effects cannot be excluded."

Spain has also withdrawn Agrippal and Fluad, which is known as Chiromas in the country.

The Spanish Agency for Medicines and Health Products (AEMPS) said it was freezing all use of both vaccines as a precautionary measure, pending a complete report based on an investigation by Novartis.

These three countries join Switzerland, Austria and Italy, all of which had already implemented bans following the discovery of contaminate vaccines in Italy.

In a statement, Novartis confirmed the contamination, but said any risk was minimal and it was “confident that there is no impact on the safety or efficacy of the vaccine”.

The company is currently working with the Italian Ministry of Health and the Italian Medicines Agency to “understand the reasons for their decision and to clarify any questions”.

In the meantime, the company has set up a website to try and answer questions from member of the public with any worries about the vaccine.

29th October 2012

From: Regulatory, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health offers a unique breadth and depth of experience, across everything from early stage product commercialisation, strategy and research,...

Latest intelligence

14_ipad_lowres.jpg
Do your customers feel that you’re listening to them?
When answering to data, excellent digital communication can create much stronger relationships between reps and customers....
Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...

Infographics